The novel anti-inflammatory phosphodiesterase-4 (PDE4) inhibitor roflumilast (Daxas®; DalirespTM) has recently been approved in the US and EU for GOLD stage 3 and 4 COPD patients. This evidence concerns the gene PDE4A and chronic obstructive pulmonary disease.